Blog
RSS FeedPosted by Michael Wonder on 01 Aug 2018
Institute for Clinical and Economic Review to evaluate comparative clinical effectiveness and value of AVXS-101 and nusinersen for spinal muscular atrophy
31 July 2018 - Open input period now open until 17 August. ...
Posted by Michael Wonder on 23 Jul 2018
Institute for Clinical and Economic Review elects three new members to governance board
23 July 2018 - New board members will bring their broad leadership experience - spanning patient advocacy, biomedical innovation, and state ...
Posted by Michael Wonder on 20 Jul 2018
ICER releases draft evidence report on inotersen and patisiran for hereditary transthyretin amyloidosis
20 July 2018 - Public comment period now open until 17 August; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 12 Jul 2018
ICER releases draft evidence report on anti-androgen therapies for non-metastatic castration-resistant prostate cancer
12 July 2018 - Public comment period now open until 9 August; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 03 Jul 2018
ICER's final report on CGRP inhibitors for migraine prevention explores specific coverage policy options in light of responsible manufacturer pricing
3 July 2018 - Report notes the significant remaining uncertainty about the long-term safety of CGRP inhibitors given their new mechanism ...
Posted by Michael Wonder on 03 Jul 2018
Institute for Clinical and Economic Review announces departure of Dan Ollendorf; launches search for new Chief Scientific Officer
3 July 2018 - The ICER announced today that Chief Scientific Officer Dan Ollendorf will be leaving to take up a ...
Posted by Michael Wonder on 27 Jun 2018
ICER to evaluate whether price increases on prescription drugs are unsupported by new clinical evidence
27 June 2018 - Initial annual report to be issued in first quarter of 2019. ...
Posted by Michael Wonder on 18 Jun 2018
ICER to assess canakinumab for atherosclerosis
18 June 2018 - Review will be subject of January Midwest CEPAC meeting; open Input now being accepted until 5 ...
Posted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst ...
Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount ...
Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future ...
Posted by Michael Wonder on 01 Jun 2018
New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B
31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their ...
Posted by Michael Wonder on 31 May 2018
ICER finds price of erenumab aligns with clinical benefit in patients for whom other therapies have failed to prevent migraines
31 May 2018 - Clinical benefits similar to other new CGRP inhibitors included in review. ...
Posted by Michael Wonder on 15 May 2018
ICER posts draft scoping document on biologic treatments for asthma
15 May 2018 - Document open to public comment until 5 June 2018. ...
Posted by Michael Wonder on 15 May 2018
Americans thought they would get a PHARMAC from Trump
15 May 2018 - If New Zealand was showing any interest in a bilateral trade agreement with the United States, ...